ABOUT DR. KANTER

A native of Boston, Alan Kanter received his M.D. degree from the University of Vermont in 1975. After his residency at Memorial Hospital in Long Beach, he practiced internal medicine in Torrance until 1990. At that time, he decided to devote his full-time to the emerging specialty of phlebology (the field of venous disorders), and took a fellowship based on European techniques recognized worldwide.

Since opening the Vein Center of Orange County, his expertise and clinical research have earned him several grants in collaboration with UCI, and a reputation as the local vein expert other doctors turn to. As a result of his published studies on the use of duplex ultrasound for real-time guidance of sclerotherapy to treat varicose veins, physicians from several continents have made the trip to Irvine to observe his treatment protocol. Dr. Kanter is a frequent speaker at the American College of Phlebology’s (ACP) Annual Congress, and has served on their Program Committee as well as committees of Public Education and Ethics & Professional Standards of Care. He has also been a guest speaker at numerous hospital and university CME courses, as well as phlebology meetings in Canada, England, Italy, and Australia. In recognition of these academic and clinical contributions, Dr. Kanter was granted “Fellow” ACP membership status in 2004.

Dr. Kanter is a member of the Orange County Medical Association, and strongly believes that his sole focus on treating venous disorders enables him to provide the highest quality service utilizing the latest technology.

Welcome to the Spring issue of Veno-gram, an educational newsletter for the practicing physician which focuses on clinical applications of current research in venous disease.

In our last issue I had promised to summarize the proceedings from the annual ACP Congress held at the Marco Island Marriott Resort in Florida last November. Unfortunately I was unable to attend the congress this year and cannot file my usual Veno-gram report. However, I will make good on my promise to share our first year’s clinical experience using endovenous laser to treat saphenous vein disease. This appears in the ‘Advances’ column where it is placed in perspective of newly published intermediate-term studies on endovenous laser. In addition, it is my pleasure to report a breakthrough in insurance reimbursement for this procedure based on a newly created CPT code.

In Other News’ announces the imminent arrival of the first oral direct thrombin inhibitor, Ximelagatran. It is my understanding that before bringing it to market in the U.S. Astra Zeneca will either change the name or include a “Hooked on Phonics” CD to assist pronunciation. Already approved in many European countries, it promises to revolutionize the treatment of venous thromboembolism. In related news an AHRQ study demonstrated the cost-effective superiority of thrombophilia testing plus 2 years anticoagulation over 6 months anticoagulation without testing for DVT. This column also covers the largest multi-center study to date on the complications of sclerotherapy, including both foam and solution. Short version: sclerotherapy is a very safe procedure with a low incidence of adverse events (0.4%) when performed by experts.

Finally, we are working on placing all Veno-gram issues on our web site for easier reference. We hope to have this accomplished in stages during the coming months. As most of you know, our www.vcoc.com web site already helps educate patients on vein disorders and prepares your referrals prior to consultation at VCOC. Besides providing a link to the ACP web site, it covers VCOC office policy, phlebology FAQs, professional background and qualifications, publications, before/after pictures, and a video of duplex ultrasound-guided injection.

The goal of this quarterly update is to disseminate the latest advances in the diagnosis and treatment of varicose veins and related disorders to primary care physicians and interested specialists. As a practicing internist since 1976, I appreciate the increasing time constraints that require us to maximize our CME time investment. I therefore pledge to provide you with concise summaries containing usable information that can make a difference in how you will treat your patients today.

You are encouraged to contact me with feedback and questions about the contents of our newsletter and website, suggestions for future issues, or reference requests. With your continued input, I hope to achieve the above-stated goal and look forward to hearing from you.

Sincerely,

Alan Kanter, M.D., FA.CPH
Founder & Medical Director

ABOUT OUR OFFICE

The Vein Center of Orange County (VCOC) is conveniently located in Irvine between the 5 & 405 Freeways. Dr. Kanter performs all consultations and treatments at VCOC, including a duplex examination at the time of consultation when indicated. Included on his team is a highly specialized vascular ultrasound technician, using the latest on-site dedicated color/flow duplex ultrasound. All referring doctors are sent timely consultation summaries and follow-up notes on their patients. Specializing primarily in the medical treatment of varicose and spider leg veins, advanced out-patient treatment for venous leg ulcers is also available. Treatment of cosmetically undesirable face, chest, and hand veins is also offered. When medical necessity exists, our friendly staff will assist patients in obtaining insurance reimbursement; however, we have opted out of Medicare, which means Medicare patients can be treated at VCOC only if they agree to forgo Medicare reimbursement. VCOC is a private fee-for-service practice, with self-supported clinical research activities since 1993. For a list of publications, brochures, or more information about our services, call 949-551-8855, or visit our www.vcoc.com web site.

Venous Disorders Update
An Educational Service from the Vein Center of Orange County                       www.vcoc.com                      Spring 2005

A Message From the Founder

Welcome to the Spring issue of Veno-gram, an educational newsletter for the practicing physician which focuses on clinical applications of current research in venous disease.

In our last issue I had promised to summarize the proceedings from the annual ACP Congress held at the Marco Island Marriott Resort in Florida last November. Unfortunately I was unable to attend the congress this year and cannot file my usual Veno-gram report. However, I will make good on my promise to share our first year’s clinical experience using endovenous laser to treat saphenous vein disease. This appears in the ‘Advances’ column where it is placed in perspective of newly published intermediate-term studies on endovenous laser. In addition, it is my pleasure to report a breakthrough in insurance reimbursement for this procedure based on a newly created CPT code.

In Other News’ announces the imminent arrival of the first oral direct thrombin inhibitor, Ximelagatran. It is my understanding that before bringing it to market in the U.S. Astra Zeneca will either change the name or include a “Hooked on Phonics” CD to assist pronunciation. Already approved in many European countries, it promises to revolutionize the treatment of venous thromboembolism. In related news an AHRQ study demonstrated the cost-effective superiority of thrombophilia testing plus 2 years anticoagulation over 6 months anticoagulation without testing for DVT. This column also covers the largest multi-center study to date on the complications of sclerotherapy, including both foam and solution. Short version: sclerotherapy is a very safe procedure with a low incidence of adverse events (0.4%) when performed by experts.

Finally, we are working on placing all Veno-gram issues on our web site for easier reference. We hope to have this accomplished in stages during the coming months. As most of you know, our www.vcoc.com web site already helps educate patients on vein disorders and prepares your referrals prior to consultation at VCOC. Besides providing a link to the ACP web site, it covers VCOC office policy, phlebology FAQs, professional background and qualifications, publications, before/after pictures, and a video of duplex ultrasound-guided injection.

The goal of this quarterly update is to disseminate the latest advances in the diagnosis and treatment of varicose veins and related disorders to primary care physicians and interested specialists. As a practicing internist since 1976, I appreciate the increasing time constraints that require us to maximize our CME time investment. I therefore pledge to provide you with concise summaries containing usable information that can make a difference in how you will treat your patients today.

You are encouraged to contact me with feedback and questions about the contents of our newsletter and website, suggestions for future issues, or reference requests. With your continued input, I hope to achieve the above-stated goal and look forward to hearing from you.

Sincerely,

Alan Kanter, M.D., FA.CPH
Founder & Medical Director

INSIDE
Endovenous Laser News
New Generation of Oral Anticoagulants
Sclerotherapy Complications
About Dr. Kanter
About Our Office